(Q54043472)

English

Gemcitabine for relapsed or resistant lymphoma.

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

Gemcitabine for relapsed or resistant lymphoma. (English)

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

author name string

D G Savage

1

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

S A Rule

2

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

M Tighe

3

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

T J Garrett

4

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

M W Oster

5

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

R T Lee

6

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

J Ruiz

7

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

D Heitjan

8

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

M L Keohan

9

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

M Flamm

10

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

S A Johnson

11

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

publication date

1 May 2000

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

11

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

5

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

595-597

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008307528519

7 January 2021

based on heuristic

inferred from DOI database lookup

Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008307528519

7 January 2021

based on heuristic

inferred from DOI database lookup

The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008307528519

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of antineoplastic activity of 2',2'-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008307528519

7 January 2021

based on heuristic

inferred from DOI database lookup

Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008307528519

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008307528519

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008307528519

7 January 2021

based on heuristic

inferred from DOI database lookup

Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg/m2) and high-dose (875 mg/m2) levels

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008307528519

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008307528519

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

24 May 2018

http://europepmc.org/abstract/MED/10907954

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54043472&oldid=1448058402"